138 related articles for article (PubMed ID: 12674195)
1. Accelerated hypertension due to rosiglitazone therapy.
Vikram NK; Misra A; Devi JR
Indian Heart J; 2002; 54(6):733. PubMed ID: 12674195
[No Abstract] [Full Text] [Related]
2. [Type 2 diabetes. A new kind of insulin sensitizer at the door].
Böhm S
MMW Fortschr Med; 1999 Jul; 141(27):56-7. PubMed ID: 10904588
[No Abstract] [Full Text] [Related]
3. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
4. Rosiglitazone monotherapy and type 2 diabetes.
Lawrence IG
Diabet Med; 2001 Nov; 18 Suppl 4():6-8. PubMed ID: 11989215
[No Abstract] [Full Text] [Related]
5. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
6. Rosiglitazone--useful drug but has side effects.
Vidhya S; Mohan V
J Assoc Physicians India; 2002 Apr; 50():615. PubMed ID: 12164432
[No Abstract] [Full Text] [Related]
7. [Rosiglitazone (BRL-49653)].
Oka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
[No Abstract] [Full Text] [Related]
8. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
9. Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Diabetes Technol Ther; 2000; 2(2):292. PubMed ID: 11469275
[No Abstract] [Full Text] [Related]
10. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
11. Warner-Lambert voluntarily withdraws Rezulin.
Diabetes Technol Ther; 2000; 2(2):290. PubMed ID: 11469273
[No Abstract] [Full Text] [Related]
12. Pioglitazone-associated fulminant hepatic failure.
Chase MP; Yarze JC
Am J Gastroenterol; 2002 Feb; 97(2):502-3. PubMed ID: 11866308
[No Abstract] [Full Text] [Related]
13. Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective.
Buse JB
Am J Manag Care; 2000 Aug; 6(13 Suppl):S710-7. PubMed ID: 11183423
[No Abstract] [Full Text] [Related]
14. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
15. New labeling and use changes for Rezulin.
Klonoff DC
Diabetes Technol Ther; 1999; 1(3):350. PubMed ID: 11484719
[No Abstract] [Full Text] [Related]
16. [Rosiglitazone: clinical data].
Blickle JF
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S27-33. PubMed ID: 12037505
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Ballary C; Desai A
J Indian Med Assoc; 2003 Feb; 101(2):113-4, 123. PubMed ID: 12841496
[TBL] [Abstract][Full Text] [Related]
18. Anticipated US approval for rosiglitazone and pioglitazone.
Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
[No Abstract] [Full Text] [Related]
19. [New insulin sensitizers].
Einecke D
MMW Fortschr Med; 1999 Oct; 141(42):6. PubMed ID: 10912094
[No Abstract] [Full Text] [Related]
20. [Thiazolidinediones in type 2 diabetes].
Baum U
Med Monatsschr Pharm; 2000 Jul; 23(7):210-3. PubMed ID: 10941251
[No Abstract] [Full Text] [Related]
[Next] [New Search]